Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MabVax Therapeutics Holdings, Inc.

http://www.mabvax.com/

Latest From MabVax Therapeutics Holdings, Inc.

Publisher’s Spotlight: Citeline Awards Honor R&D Excellence

Pharma Intelligence congratulates the winners of the 2021 Citeline Awards. 

Clinical Trials Diversity & Inclusion

Publisher’s Spotlight: Citeline Awards Honor R&D Excellence

Pharma Intelligence congratulates the winners of the 2021 Citeline Awards. 

Clinical Trials Diversity & Inclusion

Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances

Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.

Scrip Asks Coronavirus COVID-19

UCB Advances Two-Drug Strategy For Myasthenia Gravis

Successful Phase III data for UCB’s C5 inhibitor zilucoplan adds to a similarly positive Phase III readout for its rozanolixizumab in December, but details are lacking. UCB is the only company with two mechanisms for MG.

Clinical Trials Drug Approval Standards
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • MabVax Therapeutics, Inc.
    • Telik, Inc.
UsernamePublicRestriction

Register